DONACO INTERNATIONAL LIMITED (DNA)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
DNA - DONACO INTERNATIONAL LIMITED
FNArena Sector :
NONE
Year End: June
GICS Industry Group : Consumer Services
Debt/EBITDA: 1.37
Index:
FNArena Sector : NONE
Year End: June
GICS Industry Group : Consumer Services
Debt/EBITDA: 1.37
LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
---|---|---|---|
$0.034
23 Apr |
0.000 OPEN $0.03 |
0.000 HIGH $0.03 |
0 LOW $0.03 |
FNARENA'S MARKET CONSENSUS FORECASTS
- No Record -
Last ex-div: 05/10 - (franking ex-di
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
EPS Basic | xxx | xxx | xxx | xxx | xxx | -3.0 |
DPS All | xxx | xxx | xxx | xxx | xxx | 0.0 |
Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 24.3 M |
Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 9.8 |
Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | 11.3 M |
Net Profit Margin | xxx | xxx | xxx | xxx | xxx | -151.07 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | -26.93 % |
Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | -25.29 % |
Return on Assets | xxx | xxx | xxx | xxx | xxx | -19.29 % |
Return on Equity | xxx | xxx | xxx | xxx | xxx | -26.93 % |
Return on Total Capital | xxx | xxx | xxx | xxx | xxx | -4.01 % |
Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | 11.1 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Short-Term Debt | xxx | xxx | xxx | xxx | xxx | 18 M |
Long Term Debt | xxx | xxx | xxx | xxx | xxx | 9 M |
Total Debt | xxx | xxx | xxx | xxx | xxx | 27 M |
Goodwill - Gross | xxx | xxx | xxx | xxx | xxx | - |
Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | xxx | 17 M |
Price To Book Value | xxx | xxx | xxx | xxx | xxx | 0.41 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capex | xxx | xxx | xxx | xxx | xxx | 0.1 M |
Capex % of Sales | xxx | xxx | xxx | xxx | xxx | 0.55 % |
Cost of Goods Sold | xxx | xxx | xxx | xxx | xxx | 16 M |
Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | xxx | 15 M |
Research & Development | xxx | xxx | xxx | xxx | xxx | - |
Investments - Total | xxx | xxx | xxx | xxx | xxx | - |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
DNA STOCK CHART
FNArena News on DNA
1 |
Rudi’s View: Link Administration, Blue Sky And Costa GroupNov 09 2017 - Rudi's View |
2 |
Feb Reporting Season: The Interim VerdictFeb 22 2017 - Rudi's View |
3 |
Donaco Well Placed To Deliver On TargetsOct 27 2015 - Small Caps |
4 |
Earnings Upside On The Cards For DonacoOct 06 2015 - Small Caps |
5 |
Weekly Broker Wrap: Supermarkets, Automotive, Pharma And BankingJun 26 2015 - Weekly Reports |